Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Apraglutide in DCS vs Vials
NCT06002555Phase 1Completed
- Sponsor
- VectivBio
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apraglutide in short bowel syndrome (SBS) (3 arms), sponsored by VectivBio. Primary endpoints: Maximum observed plasma concentration, Area under the concentration-time curve from time zero to infinity and 1 more. Started May 2023; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT06002555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06002555.